How many shares are in the Shackelford Pharma Inc offering?
Shackelford Pharma Inc., a British Columbia corporation. A maximum of 7,500,000 Common Shares of the Company at an offering price of $1.00 per Common Share; 40,049,997 Common Shares. Common Shares to be Outstanding after the Offering:
What is Shackelford Pharma's pipeline?
Shackelford Pharma has created one of the most promising pipelines in the industry. The company is developing therapeutics for neurological conditions with an initial focus on cognitive impairment and rare epileptic disorders. "A team of doctors had me on 13 different pills.
What is the Shackelford company?
Based on Dr. Shackelford's successful clinical experience over the last decade, the Company is developing, with the intention of commercializing, unique cannabis and hemp-derived CBD based products that demonstrate effectiveness in addressing specific medical ailments or in providing wellness solutions.
Why is it difficult to evaluate Shackelford Pharma?
Shackelford Pharma Inc. has a limited operating history, which makes it difficult to accurately evaluate our business prospects.
Who is Alan Shackelford?
When will the FDA report on hemp derived CBD be released?
The Company is an early stage biopharmaceutical company dedicated to the commercial translation of the clinical knowledge and insights of Dr. Alan Shackelford, gained through his treatment of more than 25,000 patients using medical cannabis. Based on Dr. Shackelford's successful clinical experience over the last decade, the Company is developing, with the intention of commercializing, unique cannabis and hemp-derived CBD based products that demonstrate effectiveness in addressing specific medical ailments or in providing wellness solutions.
When did the FDA report on CBD?
On March 5, 2020, the FDA issued a report to Congress on how the agency intends to regulate hemp derived CBD called " Report to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations, Cannabidiol (CBD) Report in Response to Further Consolidated Appropriations Act, 2020 ".
What is a preliminary offering statement?
March 5, 2020, the FDA issued the first report to Congress in connection with the FFDCA and published a statement to update the public on its work to date on CBD, " FDA Advances Work Related to Cannabidiol Products with Focus on Protecting Public Health, Providing Market Clarity .".
What is Shackelford Pharma?
An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (the "SEC"). Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the Offering Statement filed with the SEC is qualified. This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the Offering Statement in which such Final Offering Circular was filed may be obtained.
Who is Dalmore Group LLC?
At Shackelford Pharma, Dr. Shackelford is supported by an expert medical and pharmaceutical team with a wealth of experience in clinical research and development, drug development, commercial operations, and marketing, to manage the development and commercialization of pharmaceutical products. The Company aims to provide physicians with the knowledge and confidence to prescribe cannabis-based therapies and provide patients with the certainty that the products are safe, consistent, and most importantly, effective.
What is a preliminary offering statement?
On May 27, 2020, the Company engaged Dalmore Group LLC ("Dalmore"), a New York limited liability company and broker-dealer registered with the SEC and a member of FINRA/SIPC, to provide broker-dealer services in connection with this Offering ("Broker-Dealer Agreement").
Is it safe to invest in common shares?
An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (the "SEC"). Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the Offering Statement filed with the SEC is qualified. This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the Offering Statement in which such Final Offering Circular was filed may be obtained.
Is there a sale on a stock that is more than 10% of your gross income?
Investing in our Common Shares involve a high degree of risk. These are speculative securities. You should purchase these securities only if you can afford a complete loss of your investment. See "Risk Factors" starting on page 13 for a discussion of certain risks that you should consider in connection with an investment in our securities.
What is FSD Pharma?
GENERALLY, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A FOR GENERAL INFORMATION ON INVESTING. WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV.
Who is the founder of FSD Pharma?
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") wishes to alert you to the events that have occurred since the Company filed its Management Information Circular (the "Circular") and the accompanying letter to shareholders related to the Annual & Special Meeting of shareholders scheduled for May 14, 2021, copies of which are available under the Company's SEDAR profile. On April 26, 2021, certain dissident shareholders issued an information circular which included misleading statements and baseless accusations towards the Company's management. In response, the Company issued the following letter to shareholders:
What is the Vickers top buyer and seller report?
On Tuesday, March 30, 2021, Anthony Durkacz, a founding director and member of the group of concerned shareholders, which also includes founding shareholder Zeeshan Saeed, (the "Concerned Shareholders") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (the "Company" or "FSD") received a Notice of Appeal from FSD (the "Appeal") of the March 5, 2021 decision (the "Decision") of the Ontario Superior Court of Justice (Commercial List) (the "Court"). The Decision, which resulted from an application to the Court brought by Mr. Durkacz on behalf of the Concerned Shareholders, ordered the Company to accelerate the date of its previously called annual shareholders' meeting (the "Meeting") from June 29, 2021 to May 14, 2021, retain an independent chair to preside over the Meeting and prevent Dr. Raza Bokhari and other directors from voting recently issued shares (the "Order").
What is fair value in accounting?
Daily – Vickers Top Buyers & Sellers for 06/10/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Is KCSA Psychedelics Virtual Investor Conference on demand?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
